Key facts, as of
As of October 8, 2026, DaVita Inc. (DVA) trades at $176.78, up 34.9% over the past year. Its 52-week range runs from $101.00 to $247.49; the price is 28.6% below that high. It is 28.6% below its all-time high of $247.49, reached in August 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +164.7%, against +312.9% for the S&P 500 (SPY). It sits 3.4% above its 200-day average of $170.99, the usual sign of a long-term uptrend. Its 30-day volatility is 33.5% annualized, which we rate high risk. It has a trailing P/E of 15.2.
Cite: Portfolio Terminal, "DaVita Inc. (DVA) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/dva
Where it trades today
trading 52% of the way up its 52-week range
How the price has moved
How far it is from its record
DaVita Inc. (DVA) is 28.6% below its all-time high of $247.49, reached in August 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +164.7%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- DVA trades at 15.2x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- Recent realized volatility is running around 33.5%, above the sector norm of 22.0%, so position sizing matters more than usual.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- DVA is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for DVA come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for DVA. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What DaVita Inc. does
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements;…
What analysts expect
DVA carries a buy consensus from 7 analysts, with an average price target of $219.86 versus $176.78 today (+24.4%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
DVA generated $14.01B in trailing revenue (5.2% year over year), with a 6.0% net margin, and $1.04B of free cash flow, against $12.72B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $13.64B | $4.40B | $2.01B | $746.80M | $10.06 | $1.31B |
| 2024 | $12.82B | $4.22B | $1.95B | $936.34M | $11.02 | $1.47B |
| 2023 | $12.14B | $3.82B | $1.60B | $691.53M | $7.62 | $1.49B |
| 2022 | $11.61B | $3.40B | $1.31B | $560.40M | $6.03 | $961.14M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
DVA is in 5 of the 30 ETFs we track. It weighs most in XLV: 0.10% of the fund, holding #60 of 62.
Famous investors who hold it
DVA is in the latest 13F of 1 of the 15 famous investors we follow. Warren Buffett (Berkshire Hathaway) holds the most of it: 2.15% of the portfolio, position #11 of 26, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
DVA beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 4.9% below its 50-day average and 3.4% above its 200-day.
- RSI at 43 is neither stretched nor washed out.
- The nearest ceiling is $202.63 (+14.6%), the nearest floor $157.49 (-10.9%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is DVA a good investment in 2026?
DaVita Inc. trades at a P/E ratio of 15.2, with high volatility (33.5% annualized). The stock is in a consolidation phase.
What is the risk level of DVA?
Based on 30-day volatility of 33.5%, DVA has HIGH risk. Beta of 0.80 indicates lower sensitivity to market movements than average.
Does DVA pay dividends?
DaVita Inc. currently does not pay a regular dividend.
How far is DVA from its all-time high?
DaVita Inc. is 28.6% below its all-time high of $247.49, reached in August 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +164.7%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold DVA?
5 of the 30 popular ETFs we track hold DaVita Inc.. The largest weights: XLV (0.10%), SPY (<0.01%), IVV (<0.01%), VOO (<0.01%) and VTI (<0.01%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is DVA?
<0.01%, as of August 31, 2026: DVA is holding #500 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.09 in DaVita Inc..
Which famous investors own DVA?
Warren Buffett (2.15% of Berkshire Hathaway's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
Does Warren Buffett own DVA?
Yes. Berkshire Hathaway's 13F for Q2 2026, filed August 14, 2026, lists DaVita Inc. at 2.15% of the reported portfolio, position #11 of 26.
What is the analyst price target for DVA?
The average analyst price target for DaVita Inc. (DVA) is $219.86 based on 7 analyst estimates, about 24.4% above the current price of $176.78. The published range runs from $165.00 to $270.00.
How much revenue does DVA generate?
DaVita Inc. reported $14.01B in trailing twelve-month revenue. Revenue growth is running at 5.2% year over year. Net margin sits at 6.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare DVA with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.